Global biopharmaceutical market report (2010 2015)

About IMARC For more than 5 years, the International Market Analysis Research and Consulting Group has been a

leading advisor on management strategy and market research worldwide. We partner with clients in

all sectors and regions to identify their highest-value opportunities, address their most critical

challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological

developments for business leaders in pharmaceutical, industrial, and high technology organizations.

Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food

and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of

the company's expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and

markets with close cooperation at all levels of the client organization. This ensures that our clients

achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting

results.

© IMARC®

Report Description & Highlights

The Global Biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in

1982. Today more than three hundred biopharmaceuticals have already been approved and many more are

in late stage clinical development. These drugs have not only advanced the prevention and treatment of a

number of life threatening diseases, but have also provided the thrust for the continued success of the

pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have

embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a

biopharmaceutical, however, represents a very risky proposition and out of every ten drugs that enter the

clinical phases, only three manage to gain market approval. But the industry’s US$ 92 Billion figures and

double digit growth rates in the last five years are a testimonial to the fact that the ones that finally do get

approval represent goldmines for investors.

Although factors such as biosimilar entry and cost containment in the developed markets are likely to

restrain the growth of this market in the coming years, Imarc expects that the high potency and ability of

biopharmaceuticals to attack targets beyond the reach of traditional small molecule drugs gives the industry

a huge scope for future growth. A rich late stage pipeline and the growth of emerging markets are also

expected to be major drivers for growth in the next five years. IMARC expects the global biopharmaceutical

market to reach level of sales figures worth more than US$ 167 Billion by 2015.

IMARC’s new report “Global Biopharmaceutical Market Report (2010-2015)” gives a deep insight into the

global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to

understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure,

therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till

2015. This report can serve as an excellent guide for investors, researchers, consultants, marketing

strategists, and all those who are planning to foray into the global biopharmaceutical market in some form

or the other.

Report Highlights

Biopharmaceuticals enjoy a higher approval success rate compared to traditional small molecule

drugs. They, however, require higher investments and take longer development times.

Biopharmaceuticals are significantly more expensive than traditional medications, with the annual

cost of therapy of some biopharmaceuticals touching more than a hundred thousand dollars a year.

The cost of these drugs, however, is expected to be closely scrutinized by payers in the coming

years.

© IMARC®

Recombinant Proteins represented the biggest biopharmaceutical class in 2009, accounting for more

than 65% of the total global biopharmaceutical sales. Growth in this class is expected to be low in

most of the developed markets as a result of biosimilar entry and increasing cost containment

measures.

Monoclonal Antibodies are expected to be the biggest drivers of the biopharmaceutical market in

the next five years. Driven by a rich late stage pipeline and a strong uptake from both developed

and emerging market, Monoclonal Antibodies are expected to be worth more than US$ 79 Billion by

2015.

Imarc expects the top eight markets (US, Germany, Japan, France, Italy, Spain, UK and Canada) to

account for around 79% of the total global biopharmaceutical sales by 2015. This represents a

decline of 4% over their 2009 share.

The market share of emerging markets (Brazil, Russia, India, China, Mexico, Turkey and South

Korea) is likely to increase from less than 5% in 2009 to more than 8% by 2015.

Regions/Countries Covered

Global, US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey,

Mexico, South Korea, India, Brazil, Argentina and Indonesia.

Classes Covered for Each Region/Country

Recombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins,

Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors,

Monoclonal Antibodies and Purified Proteins.

Key Features

Analysis of the key strengths, weaknesses, opportunities and threats faced by the global

biopharmaceutical market.

Exhaustive in-depth individual analysis for eighteen major developed and emerging markets.

2005 to 2009 trend analysis for the global and 18 selected biopharmaceutical markets.

2005 to 2009 trend analysis for individual biopharmaceutical classes for the global and 18 selected

biopharmaceutical markets.

2005 to 2009 trend analysis for the performance of top players for the global and 18 selected

biopharmaceutical markets.

2010-2015 sales forecast for the global and 18 selected biopharmaceutical markets.

© IMARC®

Table of Contents

1. Market Definitions & Research Methodology .............................................................................. 18

2. Analyst Briefing .............................................................................................................................. 21

3. Introduction to Biopharmaceuticals ............................................................................................. 26

4. Global Biopharmaceutical Market: Industry Analysis ................................................................ 29

4.1 Strengths ..................................................................................................................................... 29 4.1.1 High Efficacy and Target Oriented Attack ........................................................................... 29 4.1.2 Strong Potential to Achieve Blockbuster Status .................................................................. 29 4.1.3 Limited Generic Threat ........................................................................................................ 31 4.1.4 Approval Success Rates are Higher than Small Molecule Drugs ....................................... 34

4.2 Weaknesses ............................................................................................................................... 34 4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives................................................. 34 4.2.2 Second Line of Therapy ...................................................................................................... 35 4.2.3 Huge Cost of Therapy ......................................................................................................... 36 4.2.4 High Incidence of Unfavorable Side Effects ........................................................................ 37

4.3 Opportunities ............................................................................................................................... 37 4.3.1 Diseases with High Unmet Needs ....................................................................................... 37 4.3.2 Expanding the Patient Pool by Approval into Additional Indications ................................... 38 4.3.3 Emerging Markets ............................................................................................................... 39 4.3.4 Increasing New Approvals and a Strong Pipeline ............................................................... 41

4.4 Threats ........................................................................................................................................ 44 4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture ......................................... 44 4.4.2 Biosimilars ........................................................................................................................... 45 4.4.3 Limited and Conditional Reimbursement ............................................................................ 47 4.4.4 Uncertainties in the Economic Environment ....................................................................... 48

5. Global Biopharmaceutical Market: Industry Performance......................................................... 50

5.1 Market Performance & Forecast ................................................................................................. 50 5.1.1 Current Performance (2005-2009) ...................................................................................... 50 5.1.2 Market Forecasts (2010-2015) ............................................................................................ 50

5.2 Market Segmentation by Region ................................................................................................ 52 5.2.1 Current Performance (2005-2009) ...................................................................................... 52 5.2.2 Market Forecasts (2010-2015) ............................................................................................ 54

5.3 Market Segmentation by Indication ............................................................................................ 56 5.4 Market Segmentation by Class ................................................................................................... 57

5.4.1 Recombinant Proteins ......................................................................................................... 59 5.4.1.1 Current Performance (2005-2009) .............................................................................. 59 5.4.1.2 Market Forecasts (2010-2015) .................................................................................... 61

5.4.2 Monoclonal Antibodies ........................................................................................................ 63 5.4.2.1 Current Performance (2005-2009) .............................................................................. 63 5.4.2.2 Market Forecast (2010-2015) ...................................................................................... 67

5.4.3 Purified Proteins .................................................................................................................. 70 5.4.3.1 Current Performance (2005-2009) .............................................................................. 70 5.4.3.2 Market Forecast (2010-2015) ...................................................................................... 72

5.5 Competitive Landscape .............................................................................................................. 73 5.5.1 Top Biopharmaceutical Players .......................................................................................... 73 5.5.2 Top Biopharmaceutical Drugs ............................................................................................. 75

6. North America ................................................................................................................................. 77

6.1 US ............................................................................................................................................... 77 6.1.1 Market Performance (2005-2009) ....................................................................................... 77

© IMARC®

6.1.2 Market Segmentation by Class ........................................................................................... 77 6.1.2.1 Recombinant Proteins ................................................................................................. 78 6.1.2.2 Monoclonal Antibodies ................................................................................................ 80 6.1.2.3 Purified Proteins .......................................................................................................... 82

6.1.3 Performance of Top Players ............................................................................................... 83 6.1.4 Market Forecasts (2010-2015) ............................................................................................ 84

6.2 Canada ....................................................................................................................................... 86 6.2.1 Market Performance (2005-2009) ....................................................................................... 86 6.2.2 Market Segmentation by Class ........................................................................................... 86

6.2.2.1 Recombinant Proteins ................................................................................................. 87 6.2.2.2 Monoclonal Antibodies ................................................................................................ 89

6.2.3 Performance of Top Players ............................................................................................... 91 6.2.4 Market Forecasts (2010-2015) ............................................................................................ 92

7. Latin America .................................................................................................................................. 94

7.1 Mexico ......................................................................................................................................... 94 7.1.1 Market Performance (2005-2009) ....................................................................................... 94 7.1.2 Market Segmentation by Class ........................................................................................... 94

7.1.2.1 Recombinant Proteins ................................................................................................. 95 7.1.2.2 Monoclonal Antibodies ................................................................................................ 97 7.1.2.3 Purified Proteins .......................................................................................................... 99

7.1.3 Performance of Top Players ............................................................................................... 99 7.1.4 Market Forecasts (2010-2015) .......................................................................................... 101

7.2 Brazil ......................................................................................................................................... 102 7.2.1 Market Performance (2005-2009) ..................................................................................... 102 7.2.2 Market Segmentation by Class ......................................................................................... 102

7.2.2.1 Recombinant Proteins ............................................................................................... 103 7.2.2.2 Monoclonal Antibodies .............................................................................................. 105 7.2.2.3 Purified Proteins ........................................................................................................ 107

7.2.3 Performance of Top Players ............................................................................................. 108 7.2.4 Market Forecasts (2010-2015) .......................................................................................... 109

7.3 Argentina ................................................................................................................................... 111 7.3.1 Market Performance (2005-2009) ..................................................................................... 111 7.3.2 Market Segmentation by Class ......................................................................................... 111



8. Europe ........................................................................................................................................... 119

8.1 Germany ................................................................................................................................... 119 8.1.1 Market Performance (2005-2009) ..................................................................................... 119 8.1.2 Market Segmentation by Class ......................................................................................... 119



8.2 France ....................................................................................................................................... 128 8.2.1 Market Performance (2005-2009) ..................................................................................... 128 8.2.2 Market Segmentation by Class ......................................................................................... 128



© IMARC®

8.3 Italy ........................................................................................................................................... 136 8.3.1 Market Performance (2005-2009) ..................................................................................... 136 8.3.2 Market Segmentation by Class ......................................................................................... 136



8.4 Spain ......................................................................................................................................... 145 8.4.1 Market Performance (2005-2009) ..................................................................................... 145 8.4.2 Market Segmentation by Class ......................................................................................... 145



8.5 UK ............................................................................................................................................. 154 8.5.1 Market Performance (2005-2009) ..................................................................................... 154 8.5.2 Market Segmentation by Class ......................................................................................... 154



8.6 Russia ....................................................................................................................................... 163 8.6.1 Market Performance (2005-2009) ..................................................................................... 163 8.6.2 Market Segmentation by Class ......................................................................................... 163



8.7 Turkey ....................................................................................................................................... 173 8.7.1 Market Performance (2005-2009) ..................................................................................... 173 8.7.2 Market Segmentation by Class ......................................................................................... 173



9. Asia Pacific ................................................................................................................................... 182

9.1 Japan ........................................................................................................................................ 182 9.1.1 Market Performance (2005-2009) ..................................................................................... 182 9.1.2 Market Segmentation by Class ......................................................................................... 183



9.2 China ......................................................................................................................................... 192 9.2.1 Market Performance (2005-2009) ..................................................................................... 192 9.2.2 Market Segmentation by Class ......................................................................................... 192



© IMARC®

9.3 Australia .................................................................................................................................... 202 9.3.1 Market Performance (2005-2009) ..................................................................................... 202 9.3.2 Market Segmentation by Class ......................................................................................... 202



9.4 South Korea .............................................................................................................................. 210 9.4.1 Market Performance (2005-2009) ..................................................................................... 210 9.4.2 Market Segmentation by Class ......................................................................................... 210



9.5 India .......................................................................................................................................... 219 9.5.1 Market Performance (2005-2009) ..................................................................................... 219 9.5.2 Market Segmentation by Class ......................................................................................... 219



9.6 Indonesia .................................................................................................................................. 227 9.6.1 Market Performance (2005-2009) ..................................................................................... 227 9.6.2 Market Segmentation by Class ......................................................................................... 227



© IMARC®

List of Figures

Figure 2-1: Global Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ......................... 25 Figure 3-1: Complexity of Biopharmaceuticals ........................................................................................... 27 Figure 3-2: Sources of Biopharmaceuticals ................................................................................................ 28 Figure 4-1: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2000, 2009 & 2016 ................................................................................................................ 31 Figure 4-2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products ............................................................................................................... 32 Figure 4-3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used .................................................................................................................... 33 Figure 4-4: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %) ................................................................................................................................................................ 34 Figure 4-5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs, (in US$) ............................................................................................................................ 36 Figure 4-6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals and Small Molecule Drugs, (in US$) ........................................................................................................... 36 Figure 4-7: Emerging Biopharmaceutical Market Forecast, (in Million US$), 2009 & 2015 ....................... 40 Figure 4-8: Developed Biopharmaceutical Market Forecast, (in Million US$), 2009 & 2015 ..................... 40 Figure 4-9: Total Number of New Biopharmaceuticals Approved by the FDA (in Numbers), 1982-2009 .. 41 Figure 4-10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval, (in %), 1993-2004 ................................................................................................................................................... 43 Figure 4-11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total Pharmaceutical Market & Phase III development, (%), 2009 ..................................................................... 43 Figure 4-12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs, (in Million US$) ................................................................................................................. 44 Figure 4-13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market, (in Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09 ............................................................................. 45 Figure 4-14: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months) ........................................................................................................................ 45 Figure 4-15: Germany: Volume Share of Branded and Biosimilar Products in the Erythropoietins Alpha Market, (in %), September 2007 & April 2010 ............................................................................................ 47 Figure 4-16: Current Medicare Payer Coverage for Monoclonal Antibodies .............................................. 47 Figure 4-17: Performance of Biotech Stocks During the Financial Crisis, (in %), Jan 2008 to Dec 2008 .. 49 Figure 5-1: Global: Biopharmaceutical Market, (in Million US$), 2005-2009 .............................................. 50 Figure 5-2: Global: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015............................... 52 Figure 5-3: Global: Biopharmaceutical Market: Sales Share by Country, (in %), 2009 .............................. 53 Figure 5-4: Global: Biopharmaceutical Market Forecast: Sales Share by Country, (in %), 2015 ............... 55 Figure 5-5: Global: Biopharmaceutical Market: Sales Share by Indication, (in %), 2009 ........................... 56 Figure 5-6: Global: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 .................... 57 Figure 5-7: Global: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ........................ 57 Figure 5-8: Global: Biopharmaceutical Market Forecast: Sales by Class, (in Million US$), 2010-2015 ..... 58 Figure 5-9: Global: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2010-2015 ......... 58 Figure 5-10: Global: Recombinant Proteins Market, (in Million US$), 2005-2009 ...................................... 59 Figure 5-11: Global: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ......................... 61 Figure 5-12: Global: Recombinant Proteins Market Forecast, (in Million US$), 2010-2015 ....................... 61 Figure 5-13: Global: Recombinant Proteins Market Forecast: Sales Share by Class, (in %), 2015 .......... 63 Figure 5-14: Global: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ..................................... 64 Figure 5-15: Global: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ......................... 65 Figure 5-16: Global: Monoclonal Antibodies Market Forecast, (in Million US$), 2010-2015 ...................... 69 Figure 5-17: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class, (in %), 2015 .......... 70 Figure 5-18: Global: Purified Proteins Market, (in Million US$), 2005-2009 ............................................... 71 Figure 5-19: Global: Purified Proteins Market: Sales Share by Class, (in %), 2009 ................................... 71 Figure 5-20: Global: Purified Proteins Market Forecast, (in Million US$), 2010-2015 ................................ 72 Figure 5-21: Global: Purified Proteins Market Forecast: Sales Share by Class, (in %), 2015 ................... 73 Figure 5-22: Global Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ....................... 75 Figure 6-1: US: Biopharmaceutical Market, (in Million US$), 2005-2009 ................................................... 77

© IMARC®

Figure 6-2: US: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ......................... 78 Figure 6-3: US: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ............................. 78 Figure 6-4: US: Recombinant Proteins Market, (in Million US$), 2005-2009 ............................................. 79 Figure 6-5: US: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ................................. 80 Figure 6-6: US: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ............................................ 80 Figure 6-7: US: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ................................ 81 Figure 6-8: US: Purified Proteins Market, (in Million US$), 2005-2009 ...................................................... 82 Figure 6-9: US: Purified Proteins Market: Sales Share by Class, (in %), 2009 .......................................... 83 Figure 6-10: US: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ........................... 84 Figure 6-11: US: Biopharmaceutical Market Forecast, (in Million US$), 2009-2015 .................................. 85 Figure 6-12: US: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ...................... 85 Figure 6-13: Canada: Biopharmaceutical Market, (in Million US$), 2005-2009 ......................................... 86 Figure 6-14: Canada: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ............... 86 Figure 6-15: Canada: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .................... 87 Figure 6-16: Canada: Recombinant Proteins Market, (in Million US$), 2005-2009 .................................... 87 Figure 6-17: Canada: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ....................... 89 Figure 6-18: Canada: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ................................... 89 Figure 6-19: Canada: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ...................... 90 Figure 6-20: Canada: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 .................... 92 Figure 6-21: Canada: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .......................... 93 Figure 6-22: Canada: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .............. 93 Figure 7-1: Mexico: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................. 94 Figure 7-2: Mexico: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ................... 95 Figure 7-3: Mexico: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ....................... 95 Figure 7-4: Mexico: Recombinant Proteins Market, (in Million US$), 2005-2009 ....................................... 95 Figure 7-5: Mexico: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .......................... 97 Figure 7-6: Mexico: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ...................................... 97 Figure 7-7: Mexico: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 .......................... 98 Figure 7-8: Mexico: Purified Proteins Market, (in Million US$), 2005-2009 ................................................ 99 Figure 7-9: Mexico: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ..................... 100 Figure 7-10: Mexico: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015.......................... 101 Figure 7-11: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ............. 101 Figure 7-12: Brazil: Biopharmaceutical Market, (in Million US$), 2005-2009 ........................................... 102 Figure 7-13: Brazil: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ................. 102 Figure 7-14: Brazil: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ..................... 103 Figure 7-15: Brazil: Recombinant Proteins Market, (in Million US$), 2005-2009 ..................................... 103 Figure 7-16: Brazil: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ......................... 105 Figure 7-17: Brazil: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .................................... 105 Figure 7-18: Brazil: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ........................ 106 Figure 7-19: Brazil: Purified Proteins Market, (in Million US$), 2005-2009 .............................................. 107 Figure 7-20: Brazil: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ..................... 109 Figure 7-21: Brazil: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ............................ 109 Figure 7-22: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ................ 110 Figure 7-23: Argentina: Biopharmaceutical Market, (in Million US$), 2005-2009 ..................................... 111 Figure 7-24: Argentina: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ........... 111 Figure 7-25: Argentina: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ............... 112 Figure 7-26: Argentina: Recombinant Proteins Market, (in Million US$), 2005-2009 ............................... 112 Figure 7-27: Argentina: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .................. 114 Figure 7-28: Argentina: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .............................. 114 Figure 7-29: Argentina: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 .................. 115 Figure 7-30: Argentina: Purified Proteins Market, (in Million US$), 2005-2009 ........................................ 116 Figure 7-31: Argentina: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ............... 117 Figure 7-32: Argentina: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ..................... 118 Figure 7-33: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ......... 118 Figure 8-1: Germany: Biopharmaceutical Market, (in Million US$), 2005-2009 ....................................... 119 Figure 8-2: Germany: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ............. 120 Figure 8-3: Germany: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .................. 120 Figure 8-4: Germany: Recombinant Proteins Market, (in Million US$), 2005-2009 ................................. 120

© IMARC®

Figure 8-5: Germany: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ..................... 122 Figure 8-6: Germany: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ................................. 122 Figure 8-7: Germany: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 .................... 123 Figure 8-8: Germany: Purified Proteins Market, (in Million US$), 2005-2009 .......................................... 124 Figure 8-9: Germany: Purified Proteins Market: Sales Share by Class, (in %), 2009 .............................. 125 Figure 8-10: Germany: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ............... 126 Figure 8-11: Germany: Biopharmaceutical Market Forecast, (in Million US$), 2009-2015 ...................... 127 Figure 8-12: Germany: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .......... 127 Figure 8-13: France: Biopharmaceutical Market, (in Million US$), 2005-2009 ......................................... 128 Figure 8-14: France: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ............... 128 Figure 8-15: France: Biopharmaceutical Market: Sales Share By Class, (in %), 2005-2009 ................... 129 Figure 8-16: France: Recombinant Proteins Market, (in Million US$), 2005-2009 ................................... 129 Figure 8-17: France: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ....................... 131 Figure 8-18: France: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .................................. 131 Figure 8-19: France: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ...................... 132 Figure 8-20: France: Purified Proteins Market, (in Million US$), 2005-2009 ............................................ 133 Figure 8-21: France: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ................... 134 Figure 8-22: France: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .......................... 135 Figure 8-23: France: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ............. 135 Figure 8-24: Italy: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................. 136 Figure 8-25: Italy: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ................... 136 Figure 8-26: Italy: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ........................ 137 Figure 8-27: Italy: Recombinant Proteins Market, (in Million US$), 2005-2009 ........................................ 137 Figure 8-28: Italy: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ........................... 139 Figure 8-29: Italy: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ....................................... 139 Figure 8-30: Italy: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 .......................... 140 Figure 8-31: Italy: Purified Proteins Market, (in Million US$), 2005-2009 ................................................. 141 Figure 8-32: Italy: Biopharmaceutical Market: Sales Share of top players, (in %), 2009 ......................... 142 Figure 8-33: Italy: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .............................. 143 Figure 8-34: Italy: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .................. 144 Figure 8-35: Spain: Biopharmaceutical Market, (in Million US$), 2005-2009 ........................................... 145 Figure 8-36: Spain: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ................. 145 Figure 8-37: Spain: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ..................... 146 Figure 8-38: Spain: Recombinant Proteins Market, (in Million US$), 2005-2009 ..................................... 146 Figure 8-39: Spain: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ......................... 148 Figure 8-40: Spain: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .................................... 148 Figure 8-41: Spain: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ........................ 149 Figure 8-42: Spain: Purified Proteins Market, (in Million US$), 2005-2009 .............................................. 150 Figure 8-43: Spain: Purified Proteins Market: Sales Share by Class, (in %), 2009 .................................. 151 Figure 8-44: Spain: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ..................... 152 Figure 8-45: Spain: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ............................ 153 Figure 8-46: Spain: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ............... 153 Figure 8-47: UK: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................... 154 Figure 8-48: UK: Biopharmaceutical Market, Sales by Class, (in Million US$), 2005-2009 ..................... 155 Figure 8-49: UK: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ......................... 155 Figure 8-50: UK: Recombinant Proteins Market, (in Million US$), 2005-2009 ......................................... 156 Figure 8-51: UK: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ............................. 157 Figure 8-52: UK: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ........................................ 158 Figure 8-53: UK: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ............................ 159 Figure 8-54: UK: Purified Proteins Market, (in Million US$), 2005-2009 .................................................. 159 Figure 8-55: UK: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ......................... 161 Figure 8-56: UK: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ................................ 162 Figure 8-57: UK: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .................... 162 Figure 8-58: Russia: Biopharmaceutical Market, (in Million US$), 2005-2009 ......................................... 163 Figure 8-59: Russia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ............... 164 Figure 8-60: Russia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ................... 164 Figure 8-61: Russia: Recombinant Proteins Market, (in Million US$), 2005-2009 ................................... 165 Figure 8-62: Russia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ....................... 166

© IMARC®

Figure 8-63: Russia: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .................................. 167 Figure 8-64: Russia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ...................... 168 Figure 8-65: Russia: Purified Proteins Market, (in Million US$), 2005-2009 ............................................ 168 Figure 8-66: Russia: Purified Proteins Market: Sales Share by Class, (in %), 2009 ................................ 169 Figure 8-67: Russia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ................... 171 Figure 8-68: Russia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .......................... 171 Figure 8-69: Russia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .............. 172 Figure 8-70: Turkey: Biopharmaceutical Market, (in Million US$), 2005-2009 ......................................... 173 Figure 8-71: Turkey: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ............... 174 Figure 8-72: Turkey: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ................... 174 Figure 8-73: Turkey: Recombinant Proteins Market, (in Million US$), 2005-2009 ................................... 175 Figure 8-74: Turkey: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ....................... 176 Figure 8-75: Turkey: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ...................... 178 Figure 8-76: Turkey: Purified Proteins Market, (in Million US$), 2005-2009 ............................................ 178 Figure 8-77: Turkey: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ................... 180 Figure 8-78: Turkey: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 .......................... 180 Figure 8-79: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 .............. 181 Figure 9-1: Japan: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................ 183 Figure 9-2: Japan: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 .................. 183 Figure 9-3: Japan: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ....................... 184 Figure 9-4: Japan: Recombinant Proteins Market, (in Million US$), 2005-2009 ...................................... 184 Figure 9-5: Japan: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .......................... 186 Figure 9-6: Japan: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ...................................... 186 Figure 9-7: Japan: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ......................... 187 Figure 9-8: Japan: Purified Proteins Market, (in Million US$), 2005-2009 ............................................... 188 Figure 9-9: Japan: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...................... 190 Figure 9-10: Japan: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ........................... 191 Figure 9-11: Japan: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ............... 191 Figure 9-12: China: Biopharmaceutical Market, (in Million US$), 2005-2009 ........................................... 192 Figure 9-13: China: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ................. 193 Figure 9-14: China: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ..................... 193 Figure 9-15: China: Recombinant Proteins Market, (in Million US$), 2005-2009 ..................................... 194 Figure 9-16: China: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 ........................ 195 Figure 9-17: China: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .................................... 196 Figure 9-18: China: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ........................ 197 Figure 9-19: China: Purified Proteins Market, (in Million US$), 2005-2009 .............................................. 197 Figure 9-20: China: Purified Proteins Market: Sales Share by Class, (in %), 2009 .................................. 198 Figure 9-21: China: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ..................... 200 Figure 9-22: China: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ........................... 200 Figure 9-23: China: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ............... 201 Figure 9-24: Australia: Biopharmaceutical Market, (in Million US$), 2005-2009 ...................................... 202 Figure 9-25: Australia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ............ 202 Figure 9-26: Australia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ................ 203 Figure 9-27: Australia: Recombinant Proteins Market, (in Million US$), 2005-2009 ................................ 203 Figure 9-28: Australia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .................... 205 Figure 9-29: Australia: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ............................... 205 Figure 9-30: Australia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ................... 206 Figure 9-31: Australia: Purified Proteins Market, (in Million US$), 2005-2009 ......................................... 207 Figure 9-32: Australia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ................ 208 Figure 9-33: Australia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ....................... 209 Figure 9-34: Australia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ........... 209 Figure 9-35: South Korea: Biopharmaceutical Market, (in Million US$), 2005-2009 ................................ 210 Figure 9-36: South Korea: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 ...... 211 Figure 9-37: South Korea: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 .......... 211 Figure 9-38: South Korea: Recombinant Proteins Market, (in Million US$), 2005-2009 .......................... 212 Figure 9-39: South Korea: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .............. 213 Figure 9-40: South Korea: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ......................... 214 Figure 9-41: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ............. 215

© IMARC®

Figure 9-42: South Korea: Purified Proteins Market, (in Million US$), 2005-2009 ................................... 215 Figure 9-43: South Korea: Purified Proteins Market: Sales Share by Class, (in %), 2009 ....................... 216 Figure 9-44: South Korea: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 .......... 217 Figure 9-45: South Korea: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ................. 218 Figure 9-46: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ..... 218 Figure 9-47: India: Biopharmaceutical Market, (in Million US$), 2005-2009 ............................................ 219 Figure 9-48: India: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 .................. 220 Figure 9-49: India: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ....................... 220 Figure 9-50: India: Recombinant Proteins Market, (in Million US$), 2005-2009 ...................................... 221 Figure 9-51: India: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .......................... 222 Figure 9-52: India: Monoclonal Antibodies Market, (in Million US$), 2005-2009 ...................................... 222 Figure 9-53: India: Purified Proteins Market, (in Million US$), 2005-2009 ............................................... 223 Figure 9-54: India: Purified Proteins Market: Sales Share by Class, (in %), 2009 ................................... 224 Figure 9-55: India: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ...................... 225 Figure 9-56: India: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ............................. 226 Figure 9-57: India: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ................. 226 Figure 9-58: Indonesia: Biopharmaceutical Market, (in Million US$), 2005-2009 .................................... 227 Figure 9-59: Indonesia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009 .......... 228 Figure 9-60: Indonesia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009 ............... 228 Figure 9-61: Indonesia: Recombinant Proteins Market, (in Million US$), 2005-2009 ............................... 229 Figure 9-62: Indonesia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009 .................. 230 Figure 9-63: Indonesia: Monoclonal Antibodies Market, (in Million US$), 2005-2009 .............................. 230 Figure 9-64: Indonesia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009 ................. 231 Figure 9-65: Indonesia: Purified Proteins Market, (in Million US$), 2005-2009 ........................................ 232 Figure 9-66: Indonesia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009 ............... 233 Figure 9-67: Indonesia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015 ..................... 234 Figure 9-68: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015 ......... 234

© IMARC®

List of Tables

Table 1-1: Global: Biopharmaceutical Market: Definition & Segmentation ................................................. 19 Table 2-1: Global: Biopharmaceutical Market: SWOT Analysis ................................................................. 21 Table 2-2: Global: Recombinant Proteins Market Forecast: Sales by Class, (in Million US$), 2009 & 2015 .................................................................................................................................................................... 22 Table 2-3: Global: Monoclonal Antibodies Market Forecast: Sales by Class, (in Million US$), 2009 & 2015 .................................................................................................................................................................... 23 Table 2-4: Global: Purified Proteins Market Forecast: Sales by Class, (in Million US$), 2009 & 2015 ...... 23 Table 2-5: Global: Biopharmaceutical Market Forecast: Sales by Region, (in Million US$), 2009 & 2015 24 Table 3-1: Differences Between Small Molecule Drugs & Biopharmaceuticals ......................................... 26 Table 3-2: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs ........................................................................................................................................................... 28 Table 4-1: Global: Top Ten Selling Drugs (Based on Origin), 2000 ........................................................... 30 Table 4-2: Global: Top Ten Selling Drugs (Based on Origin), 2009 ........................................................... 30 Table 4-3: Global: Top Ten Selling Drugs Forecast (Based on Origin), 2016 ............................................ 31 Table 4-4: Mode of Administration of Popular Biotech Drugs ..................................................................... 35 Table 4-5: FDA: Total Number of Biopharmaceutical Approvals in 2009 ................................................... 42 Table 4-6: US and European Statistics of Branded Biopharmaceutical Products Facing Biosimilar Threat, (in Million US$), 2009 .................................................................................................................................. 46 Table 5-1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2005-2009 .................. 53 Table 5-2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2010-2015 ... 55 Table 5-3: Global: Biopharmaceutical Market: Sales by Indication, (in Billion US$), 2009 ........................ 56 Table 5-4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth, (in Million US$), 2009-2015 ................................................................................................................................................... 59 Table 5-5: Global: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ............... 60 Table 5-6: Global: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ................... 60 Table 5-7: Global: Recombinant Proteins Market Forecast: Sales by Class, (in %), 2010-2015 ............... 62 Table 5-8: Global: Recombinant Proteins Market Forecast: Sales Share by Class, (in %), 2010-2015 .... 62 Table 5-9: Global: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .............. 64 Table 5-10: Global: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ................. 64 Table 5-11: Global: Humanized Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009 .................................................................................................................................................. 65 Table 5-12: Global: Chimeric Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009 ............................................................................................................................................................ 66 Table 5-13: Global: Fully Human Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009 .................................................................................................................................................. 66 Table 5-14: Global: Murine Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009 ............................................................................................................................................................ 66 Table 5-15: Global: Murine Monoclonal Antibodies in Phase-III Development ......................................... 67 Table 5-16: Global: Chmeric Monoclonal Antibodies in Phase-III Development ........................................ 68 Table 5-17: Global: Humanized Monoclonal Antibodies in Phase-III Development ................................... 68 Table 5-18: Global: Fully Human Monoclonal Antibodies in Phase-III Development ................................. 68 Table 5-19: Global: Immunotoxins in Phase-III Development ................................................................... 69 Table 5-20: Global: Monoclonal Antibodies Market Forecast: Sales by Class, (in Million US$), 2010-2015 .................................................................................................................................................................... 69 Table 5-21: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class, (in %), 2010-2015.. 70 Table 5-22: Global: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ...................... 71 Table 5-23: Global: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 .......................... 71 Table 5-24: Global: Purified Proteins Market Forecast: Sales by Class, (in Million US$), 2010-2015 ....... 72 Table 5-25: Global: Purified Proteins Market Forecast: Sales Share by Class, (in %), 2010-2015 ........... 72 Table 5-26: Global: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ......... 74 Table 5-27: Global: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 .............. 74 Table 5-28: Global: Biopharmaceutical Market; Sales Forecast of Top Biopharmaceuticals, (in Million US$), 2009 & 2016 ...................................................................................................................................... 76 Table 6-1: US: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .................... 79 Table 6-2: US: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ......................... 79

© IMARC®

Table 6-3: US: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .................... 81 Table 6-4: US: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ........................ 81 Table 6-5: US: Purified Proteins Market: Sales by Class, 2005-2009 ........................................................ 82 Table 6-6: US: Purified Proteins Market: Sales Share by Class, 2005-2009 ............................................. 82 Table 6-7: US: Biopharmaceutical Market: Sales of Top Players, (in US$), 2005-2009 ............................ 83 Table 6-8: US: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ..................... 84 Table 6-9: Canada: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ............. 88 Table 6-10: Canada: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ............... 88 Table 6-11: Canada: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .......... 90 Table 6-12: Canada: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .............. 90 Table 6-13: Canada: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ....... 91 Table 6-14: Canada: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............. 91 Table 7-1: Mexico: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .............. 96 Table 7-2: Mexico: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 .................. 96 Table 7-3: Mexico: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ............. 98 Table 7-4: Mexico: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .................. 98 Table 7-5: Mexico: Purified Proteins Market: Sales by Class (in Million US$), 2005-2009 ........................ 99 Table 7-6: Mexico: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ....... 100 Table 7-7: Mexico: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ............. 100 Table 7-8: Brazil: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .............. 104 Table 7-9: Brazil: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ................... 104 Table 7-10: Brazil: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ............ 106 Table 7-11: Brazil: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ................ 106 Table 7-12: Brazil: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..................... 107 Table 7-13: Brazil: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 .......................... 107 Table 7-14: Brazil: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ......... 108 Table 7-15: Brazil: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 .............. 108 Table 7-16: Argentina: Recombinant Proteins Market: Sales by Class, 2005-2009 ................................. 113 Table 7-17: Argentina: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 .......... 113 Table 7-18: Argentina: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ..... 115 Table 7-19: Argentina: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .......... 115 Table 7-20: Argentina: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ............... 116 Table 7-21: Argentina: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .. 116 Table 7-22: Argentina: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ....... 117 Table 8-1: Germany: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ......... 121 Table 8-2: Germany: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ............. 121 Table 8-3: Germany: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ........ 123 Table 8-4: Germany: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ............ 123 Table 8-5: Germany: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 .................. 124 Table 8-6: Germany: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ...................... 124 Table 8-7: Germany: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ..... 125 Table 8-8: Germany: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ......... 126 Table 8-9: France: Recombinant Proteins Market: Sales by Class,(in Million US$), 2005-2009 ............. 130 Table 8-10: France: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ............... 130 Table 8-11: France: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ......... 132 Table 8-12: France: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .............. 132 Table 8-13: France: Purified Proteins Market: Sales by Class, 2005-2009 .............................................. 133 Table 8-14: France: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ....... 134 Table 8-15: France: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............ 134 Table 8-16: Italy: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ............... 138 Table 8-17: Italy: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ................... 138 Table 8-18: Italy: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .............. 140 Table 8-19: Italy: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .................. 140 Table 8-20: Italy: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ........................ 141 Table 8-21: Italy: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ............................ 141 Table 8-22: Italy: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ........... 142 Table 8-23: Italy: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ................. 142 Table 8-24: Spain: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ............ 147

© IMARC®

Table 8-25: Spain: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ................. 147 Table 8-26: Spain: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ........... 149 Table 8-27: Spain: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ................ 149 Table 8-28: Spain: Purified Proteins Market: Sales by Class, 2005-2009 ................................................ 150 Table 8-29: Spain: Purified Proteins Market: Sales Share by Class, 2005-2009 ..................................... 150 Table 8-30: Spain: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ......... 151 Table 8-31: Spain: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ............. 152 Table 8-32: UK: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ................ 156 Table 8-33: UK: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ..................... 157 Table 8-34: UK: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ................ 158 Table 8-35: UK: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .................... 158 Table 8-36: UK: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ......................... 160 Table 8-37: UK: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 .............................. 160 Table 8-38: UK: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ............. 161 Table 8-39: UK: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ................. 161 Table 8-40: Russia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .......... 165 Table 8-41: Russia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ............... 166 Table 8-42: Russia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .......... 167 Table 8-43: Russia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .............. 167 Table 8-44: Russia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ................... 169 Table 8-45: Russia: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ........................ 169 Table 8-46: Russia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ....... 170 Table 8-47: Russia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............ 170 Table 8-48: Turkey: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .......... 175 Table 8-49: Turkey: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ............... 176 Table 8-50: Turkey: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 .......... 177 Table 8-51: Turkey: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 .............. 177 Table 8-52: Turkey: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ................... 179 Table 8-53: Turkey: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ....... 179 Table 8-54: Turkey: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............ 179 Table 9-1: Japan: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .............. 185 Table 9-2: Japan: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 .................. 185 Table 9-3: Japan: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ............. 187 Table 9-4: Japan: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ................. 187 Table 9-5: Japan: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ....................... 188 Table 9-6: Japan: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ........................... 188 Table 9-7: Japan: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .......... 189 Table 9-8: Japan: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............... 189 Table 9-9: China: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .............. 194 Table 9-10: China: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ................ 195 Table 9-11: China: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ........... 196 Table 9-12: China: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ................ 196 Table 9-13: China: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ..................... 198 Table 9-14: China: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ......................... 198 Table 9-15: China: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 ........ 199 Table 9-16: China: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 ............. 199 Table 9-17: Australia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ....... 204 Table 9-18: Australia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ............ 204 Table 9-19: Australia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ....... 206 Table 9-20: Australia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ........... 206 Table 9-21: Australia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ................ 207 Table 9-22: Australia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .... 207 Table 9-23: Australia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ......... 208 Table 9-24: South Korea: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 . 212 Table 9-25: South Korea: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 ...... 213 Table 9-26: South Korea: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009. 214 Table 9-27: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ..... 214 Table 9-28: South Korea: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 .......... 216

© IMARC®

Table 9-29: South Korea: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ............... 216 Table 9-30: South Korea: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .................................................................................................................................................................. 217 Table 9-31: South Korea: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009 .. 217 Table 9-32: India: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 .............. 221 Table 9-33: India: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 .................. 221 Table 9-34: India: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ............. 223 Table 9-35: India: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ....................... 223 Table 9-36: India: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009 ........................... 223 Table 9-37: India: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .......... 224 Table 9-38: India: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ............... 225 Table 9-39: Indonesia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009 ...... 229 Table 9-40: Indonesia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009 .......... 229 Table 9-41: Indonesia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009 ..... 231 Table 9-42: Indonesia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009 ......... 231 Table 9-43: Indonesia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009 ............... 232 Table 9-44: Indonesia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009 .. 233 Table 9-45: Indonesia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009 ........ 233

© IMARC®

Prices and Order Information

Single user license PDF

Single user license CD ROM

Single user license Hard Copy

Multiple User License All Formats

US$ 1,000 US$1,200 US$1,200 US$1,800

I would like to order the market Study “Global

Biopharmaceutical Market Report (2010-2015)”

Your Name:

Job Title:

Company:

Email Id:

Telephone Number:

Address:

Krishna Sharma

International Market Research Analysis and Consulting Group

91-11-43095788

[email protected]

Kindly Complete Your Details

Contact IMARC Group

Business

Global biopharmaceutical market report (2010 2015)